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Abstract
Intramuscular injections are contra-indicated in infants with either acquired 
or congenital bleeding disorders. In such patients, it is unlicensed practice to 
administer vaccines by subcutaneous route. However, there are no reports on 
subcutaneous administration of palivizumab (Synagis®). We report on the 
tolerance and effects of subcutaneous palivizumab administration in a former 
preterm girl with type 2B von Willebrand disease. Repeated subcutaneous 
injections of palivizumab were well tolerated with minor local reactions and 
no systemic side effects. 
Consequently, we suggest to consider the subcutaneous instead of the 
intramuscular route in a setting of a valid indication for palivizumab, but 
a contraindication for intramuscular administration. More importantly, 
off-label or unlicensed practices should be reported to share and improve 
pharmacotherapy or at least illustrate knowledge gaps.
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Introduction
Infants with bleeding disorders should receive 
the recommended immunizations for their age 
group, but should preferably receive the vaccine 
subcutaneously rather than intramuscularly or 
intradermally, unless covered – when applicable – 
by infusion of clotting factor concentrates (level 4 
of evidence) [1]. This is because an intramuscular 
bleeding does not only result in acute pain and 
impairment, but may also result in muscular fibrosis 
and permanent dysfunction. Such coagulation 
disorders can either be congenital (e.g. hemophilia 
A or B, von Willebrand disease), or acquired (e.g. 
during anticoagulation). In these cases, there is 
the unlicensed practice to administer vaccines 
by subcutaneous route. This practice has been 
reported for example for hepatitis B vaccination 
[2]. Despite extensive literature search, we were 
unable to retrieve any published experience on 
the use of the subcutaneous route for palivizumab 
(Synagis®, Abbvie, Wavre, Belgium). Synagis® 
is labeled for intramuscular injection and the label 
only suggests that “Synagis® should be given with 
caution to children with thrombocytopenia or any 
coagulation disorder” [3]. 
However, there are a lot of polyclonal and 
monoclonal antibody formulations that are 
administered by subcutaneous route. Moreover, 
pharmacokinetic studies on monoclonal or 
polyclonal antibodies following either intramus- 
cular or subcutaneous administration reported 
similar peak and through values [4]. Further 
supported by a mathematical description for 
subcutaneous or intramuscular administration 
of monoclonal antibodies [5], we decided to 
administer palivizumab by subcutaneous route (15 
mg/kg/month) and to document the effects in a 
former preterm girl diagnosed with type 2B von 
Willebrand disease. 
Case presentation
The presented case regards a girl that was 
born as the third child from a mother with 
known type 2B von Willebrand disease at the 
gestational age of 34 weeks and a birth weight 
of 2.4 kg, and subsequently needed respiratory 
support and additional oxygen in the first week 
of life. Based on the prolonged activated partial 
thromboplastin time (aPTT), a reduced von 
Willebrand factor ristocetine cofactor activity 
(39%) and thrombocytopenia (18  x  109/L), the 
diagnosis of type 2B von Willebrand disease 
was suspected, and subsequently confirmed by 
genetic testing. Further neonatal stay in the 
hospital was without additional problems, but 
she displayed an apparent life threatening event 
(ALTE) at the age of 2 months (42 weeks of 
corrected age) at the outpatient clinic. During a 
diagnostic blood sampling, the infant collapsed 
with bradycardia, desaturation and hypotonia, 
and needed basic resuscitation (stimulation, 
oxygen, bag ventilation). During subsequent 
admission, gastro-oesophageal reflux was 
suspected while respiratory syncytial virus (RSV) 
antigen detection in a nasopharyngeal aspirate 
at that time was negative. Based on the preterm 
birth (approved indication for reimbursement 
in Belgium for preterm neonates < 35 weeks of 
gestational age, if respiratory support > 48 hours 
after birth was needed, and if the first 6 months 
of postnatal life are during the RSV season), and 
further supported by the ALTE event, we felt that 
there were good arguments in support of RSV 
prophylaxis. 
Although this is an unlicensed practice not 
supported by published experience, we felt that 
subcutaneous administration of palivizumab was 
appropriate in line with published guidelines [1]. 
This decision was also based on extrapolation from 
other polyclonal and monoclonal antibodies [4, 
5]. Despite these supporting guidelines, we only 
retrieved one similar case, however not reported 
in the public domain. Following contact with the 
medical advisors of the manufacturer, the company 
informed us that they had access to one other 
case report (male former preterm infant, warfarin 
treatment following thrombosis of the vena cava 
inferior) treated with subcutaneous palivizumab [6]. 
The rationale and the available options were 
discussed with the parents. Following parental 
consent, we decided to document prospectively the 
tolerance and effects of subcutaneous palivizumab 
administration in this former preterm girl. Spare 
plasma samples (peak and through levels) were also 
collected, but analysis was not possible since we had 
no access to the only valid quantification technique 
(copyright owned, not readily available). The girl 
received 5 monthly subcutaneous injections (15 mg/
kg, in either the left or right upper leg, weight range 
4.6 to 6.6 kg) and was subsequently monitored by a 
physician (KA) during at least 1 hour for systemic 
and local side effects with subsequent evaluation 
of tolerance by the parents. The parents reported 
that the local tolerance of palivizumab (tenderness, 
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swelling) was in fact much better when compared 
to the simultaneously administered (Infarix Hexa®, 
GlaxoSmithKline Biologicals, Rixensart, Belgium 
or Prevenar®, Pfizer, Puurs, Belgium, both also 
subcutaneous) vaccines. She never displayed RSV-
related symptoms. 
Discussion
We report the first case of repeated subcutaneous 
administration of Palivizumab in a former pre- 
term infant with a congenital bleeding disorder. 
Repeated subcutaneous injection of palivizumab 
was well tolerated with minor local reactions 
and no systemic side effects. Consequently, we 
suggest to consider the subcutaneous instead of 
the intramuscular route in the setting of a valid 
indication for palivizumab, but a contraindication for 
intramuscular administration. 
Besides compound specific information, this case 
report may also serve as an illustration on the need 
to report more on off-label or unlicensed practices in 
neonates and infants to share and improve knowledge 
on pharmacotherapy [7, 8]. Exposure to off-label 
use or unlicensed practices is not by definition 
unnecessary exposure without benefit or indication 
[7, 8]. At present, there are still many effective and 
reported treatments for neonates that are not included 
in the drug label. It is very unlikely that there were 
no other preterm neonates between 1999 and 2014 
with either acquired or congenital bleeding disorders 
with an indication for palivizumab treatment. Since 
the label suggests that “Synagis® should be given 
with caution to children with thrombocytopenia or 
any coagulation disorder” [3], it is up to clinicians 
to decide what this “caution” covers and to report 
on the (side-)effects of their decisions. To further 
illustrate this approach, we refer to the reported 
practice to consider intravenous palivizumab as a 
treatment option for persistent RSV infection among 
immunocompromised pediatric patients: off-label, 
unlicensed, but of potential benefit in this very 
specific and extraordinary setting [9]. 
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